The Scientist - Home

The symptoms suggest SARS-CoV-2 might infect neurons, raising questions about whether there could be effects on the brain that play a role in patients’ deaths, but the data are preliminary.

As scores of academic meetings get upended due to COVID-19, researchers are turning to virtual replacements.

We present an economic plan for a collective sharing of scientific knowledge on the pandemic.

President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.

Under lockdown in a hotel, members of a plant ecology course continue to work and study as they seek a way to return home.

The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?

With mounting feelings of isolation, research projects derailed, and financial futures cast into doubt, grad students are anxious in the midst of the COVID-19 outbreak.

Rhesus macaques can be infected with SARS-CoV-2, leading primate center scientists to try to prevent outbreaks in their colonies, especially as experiments on coronavirus start.

Flexible proteins appear to protect molecules from becoming denatured in extreme conditions such as heat and from clumping up, as happens in some neurodegenerative diseases.

Here are the lessons we’ve learned so far about the keys to virtual science education—including what to do about lab classes.

The World Health Organization warns that a lack of data on how many people have the disease could undermine containment and mitigation efforts in many countries.

Labs are trying to figure out who will care for animals and organoids and some clinical trials are put on hold.